Phase I/II Trial: BIBF 1120 Added to Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia (AML)
NCT01488344
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
UNKNOWN
Status
140
Enrollment
OTHER
Sponsor class
Conditions
Acute Myeloid Leukemia
Interventions
DRUG:
triple kinase inhibitor BIBF1120
Sponsor
University Hospital Muenster
Collaborators
[object Object]